Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Kutaisis Akhali #2 Sams… | Healthcare Services | 22.6% | 82nd pct | 268 |
| Abastumnis Piltvis Tsen… | Healthcare Services | 21.0% | 78th pct | 268 |
| Estelaini | Healthcare Services | 16.7% | 70th pct | 268 |
| Libertasi | Healthcare Services | 10.9% | 54th pct | 268 |
| Malkhaz Katsiashvilis M… | Healthcare Services | -23.0% | 8th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Malkhaz Katsiashvilis M… | Estelaini | Kutaisis Akhali #2 Sams… | Libertasi | Abastumnis Piltvis Tsen… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 82.5% | 83.5% | 90.1% | 88.7% | 100.0% |
| EBITDA Margin | -23.0% | 16.7% | 22.6% | 10.9% | 21.0% |
| EBITDAR | -649 | 610 | 601 | 579 | 519 |
| EBITDAR Margin | -23.0% | 22.2% | 22.7% | 23.3% | 21.0% |
| EBIT Margin | -29.0% | 9.3% | 16.8% | 10.8% | -0.4% |
| Net Profit Margin | -45.5% | 5.2% | 15.3% | 10.7% | -0.4% |
| Operating Expense % of Sales | 105.4% | 66.7% | 67.5% | 77.8% | 79.0% |
| Returns | |||||
| Return on Assets (ROA) | -17.2% | 5.5% | 14.4% | 74.9% | -0.1% |
| Return on Equity (ROE) | N/A | 6.7% | 15.1% | 123.5% | -0.1% |
| ROIC [EBIT / Invested Capital] | -16.4% | 13.8% | 17.7% | 127.4% | -0.1% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 70.7% | 0.0% | 0.0% | 20.7% | 0.0% |
| Debt-to-Equity | -34.64x | 0.00x | 0.00x | 0.34x | 0.00x |
| Debt-to-EBITDA | N/A | 0.00x | 0.00x | 0.27x | 0.00x |
| Equity-to-Assets | -2.0% | 81.6% | 95.1% | 60.7% | 99.8% |
| Net Debt | 5,156 | -277 | -163 | -4 | -149 |
| Cash & Equivalents | 144 | 277 | 163 | 77 | 149 |
| Total Debt | 5,300 | N/A | N/A | 73 | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 0.00x | 1.03x | 4.26x | 1.21x | 10.51x |
| Quick Ratio | 0.00x | 1.03x | 4.26x | 1.21x | 10.51x |
| Cash Ratio | 0.23x | 0.58x | 1.16x | 0.55x | 7.73x |
| Total Current Assets | 0 | 494 | 599 | 169 | 203 |
| Total Current Liabilities | 619 | 481 | 141 | 139 | 19 |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Trade Receivables | 691 | 8 | 591 | 10 | 154 |
| Trade Payables | 616 | 9 | 41 | 45 | 19 |
| Net Working Capital | -619 | 13 | 459 | 30 | 184 |
| Net Working Capital % of Revenue | -21.9% | 0.5% | 17.3% | 1.2% | 7.4% |
| Trade Working Capital | 75 | -1 | 550 | -36 | 134 |
| Trade Working Capital % of Revenue | 2.7% | -0.0% | 20.8% | -1.4% | 5.4% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 4.09x | 336.37x | 4.48x | 258.30x | 16.11x |
| Days Sales Outstanding (DSO) | 89.3 | 1.1 | 81.4 | 1.4 | 22.7 |
| Payables Turnover | 0.81x | 48.96x | 6.46x | 6.19x | N/A |
| Days Payable Outstanding (DPO) | 453.3 | 7.5 | 56.5 | 58.9 | N/A |
| Cash Conversion Cycle | -364.0 days | -6.4 days | 24.9 days | -57.5 days | 22.7 days |
| Asset Turnover | 0.38x | 1.05x | 0.94x | 7.03x | 0.21x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 334 | -677 | 2,472 | 0 | -2 |
| Free Cash Flow (OCF − Capex proxy) | 334 | -677 | 2,472 | 0 | -2 |
| Cash Conversion (OCF / EBITDA) | N/A | -147.1% | 413.4% | 0.0% | -0.3% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |